Molecular biology of castration-resistant prostate cancer

Castration-resistant prostate cancer was subjected to a paradigm switch from hormone resistance to androgen deprivation therapy resistance during the last decade.

Indeed, new therapeutics targeting the androgen receptor showed clinical efficacy in patients with progressive disease under castration.

Thus, it is a proof that the AR remains a dominant driver of oncogenesis in earlier-called hormone resistant prostate cancer.

This review summarizes the molecular mechanisms involved in castration-resistant prostate cancer.

Bull Cancer. 2015 Jun;102(6):497-500. doi: 10.1016/j.bulcan.2015.04.014. Epub 2015 May 28.

[Article in French]
Doucet L1, Terrisse S2, Gauthier H3, Pouessel D3, Le Maignan C3, Teixeira L2, Culine S2.

1AP-HP, hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, UFR de médecine, 75890 Paris cedex 18, France. 
2AP-HP, hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, UFR de médecine, 75890 Paris cedex 18, France.
3AP-HP, hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France.